← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
Colorado dexamethasone versus prednisone SSNHL study
Also known as: High-dose oral steroids in SSNHL, Dexamethasone versus prednisone, NCT03255473
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Steroid/Anti-inflammatory
Stage
Phase 2
Status
Discontinued
Target Gene
—
Route / Mode
Oral
Confidence
74%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
United States
Population
adult, sudden, sensorineural, study-level
Trial IDs
1
Mechanism
Withdrawn randomized Phase 2 academic study comparing hearing outcomes and side effects for oral dexamethasone versus oral prednisone in unilateral sudden sensorineural hearing loss.
Indications
Notes
Split out from the broad dexamethasone cluster. ClinicalTrials.gov verifies a withdrawn University of Colorado Phase 2 steroid-comparator study in SSNHL; this is a generic corticosteroid comparison, not a proprietary program.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT03255473
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-verified-studydiscontinued-registry-studygeneric-drug-studystudy-level-not-standalone-productnot-commercial-pipeline-program
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2